Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-shogaol is a bioactive phytochemical and pungent constituent derived from ginger (*Zingiber officinale*), specifically formed through the dehydration of 8-gingerol during storage or thermal processing. It is being investigated for its vasorelaxant properties, particularly its ability to relax pre-contracted pulmonary arteries. The compound's mechanism of action involves the inhibition of phospholipase C (PLC), a key enzyme in the constriction-relaxation pathway of smooth muscle. By inhibiting PLC, 8-shogaol attenuates endothelin-1 (ET1)-stimulated increases in intracellular calcium within pulmonary artery smooth muscle cells (PASMC). This pharmacological profile suggests potential therapeutic application in the management of vascular hypertensive disorders, including pulmonary hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-shogaol.